BridgeMD
New treatment option for Newly Diagnosed Glioblastoma
Official title Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
ClinicalTrials.gov ID: NCT05864534
What this study is testing
What is Balstilimab?
Balstilimab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for newly diagnosed glioblastoma.
Also referred to as BAL.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have newly diagnosed pathologically proven glioblastoma, isocitric dehydrogenase-1/2 wild-type
- Tumor with methyl guanine methyl transferase (MGMT) gene promoter unmethylated
- Available paraffin embedded tumor tissue for the study
- Have completed standard radiotherapy with or without temozolomide
- 18 years of age or older
You likely can't join if
- Patients will be ineligible if they have:
- Multifocal tumor (unless all localized in a 50-mm diameter area accessible to ultrasound field) or tumor located in the posterior fossa.
- Uncontrolled epilepsy.
- Received other investigational agents within 2 weeks of registration
- Received prior therapy with or have history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used...
- Contraindication to checkpoint inhibitor therapy (e.g., history of autoimmune disease)
See the full eligibility criteria
- Have newly diagnosed pathologically proven glioblastoma, isocitric dehydrogenase-1/2 wild-type
- Tumor with methyl guanine methyl transferase (MGMT) gene promoter unmethylated
- Available paraffin embedded tumor tissue for the study
- Have completed standard radiotherapy with or without temozolomide
- 18 years of age or older
- Able to undergo contrast-enhanced MRI
- Have an Eastern Cooperative Oncology Group/World Health Organization performance status ≤ 2
- Size and location of the residual tumor and/or resection cavity must allow to be able to be covered by the sonication field
- Have not received any prior treatment with immunotherapeutic agents treatments for glioblastoma or other indications
- Have the ability to understand and willingness to sign a written informed consent prior to registration on study.
- Be willing and able to comply with the protocol.
- Have adequate organ and bone marrow function
- Agree to use adequate contraception if appropriate
- Patients will be ineligible if they have:
- Multifocal tumor (unless all localized in a 50-mm diameter area accessible to ultrasound field) or tumor located in the posterior fossa.
- Uncontrolled epilepsy.
- Received other investigational agents within 2 weeks of registration
- Received prior therapy with or have history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study.
- Contraindication to checkpoint inhibitor therapy (e.g., history of autoimmune disease)
- Uncontrolled illness
- History of active malignancy other than the brain tumor within 12 months prior to registration.
- Are pregnant or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.